Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine in platinum-sensitive ovarian cancer with high FRα expression
NCT05041257Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AbbVie Inc.. Started Oct 2021; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05041257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041257.